POTENTIAL APPLICATIONS FOR EPIGENETIC PHARMACOLOGY
Several neuropsychiatric areas can be identified at present that could represent where the future
might lie in terms of mC-targeted therapeutics. We discuss these in more detail in the final section
of this review. However, all these areas are highly speculative and not yet at the stage of actual
drug development endeavors. As discussed above, the existing literature regarding how DNA
methylation is altered in the CNS is much more broad and well developed than literature describing
drugs designed to target these mechanisms. Indeed, literature describing the use of drugs that target
DNA methylation in any human pathology is essentially absent outside of developing efforts using
DNMT inhibitors to slow cancer progression (101–104).